Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. is a high-tech enterprise specializing in the R&D, production, and sales of high-value-added pharmaceutical intermediates and APIs.The company is committed to providing the global pharmaceutical industry with key materials and innovative solutions.
At the recent CPHI China 2025, Mr. Zheng, General Manager of Shanghai Lizhuo Pharmaceutical Technology Co., Ltd., was invited to give an exclusive interview to CCTV. In the interview, Mr. Zheng systematically introduced the recent development of Lizhuo Pharmaceutical and provided an in-depth analysis and outlook on the current dynamics, trends, and future directions of the global and Chinese innovative drug markets.
![5-氟-1-(2-氟苄基)-1H-吡唑并[3,4-B]吡啶-3-甲酸乙酯CAS NO.1361232-72-5](http://www.shlzpharma.com/uploads/5-氟-1-2-氟苄基-1H-吡唑并34-B吡啶-3-甲酸乙酯CAS-NO.1361232-72-51.png)
Mr. Zheng pointed out in the interview that with the continued rise in the global incidence of chronic and metabolic diseases, the R&D and production of related innovative drugs are ushering in significant opportunities. He specifically mentioned that Lizhuo Pharmaceutical recently achieved the industrial-scale mass production of intermediates for two important drugs: finerenone and vericiguat. These include intermediates for finerenone (CAS: 21962-45-8) and 4-amino-5-methylpyridin-2-ol (CAS: 95306-64-2), both intermediates for the active pharmaceutical ingredient finerenone used to treat diabetic nephropathy, chronic kidney disease, and end-stage renal disease; and ethyl 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (CAS: 1361232-72-5), produced for the oral drug vericiguat used to treat chronic heart failure. Since their market launch, these high-purity intermediates have gained widespread recognition and praise from domestic and international customers due to their excellent quality and stable supply.
Furthermore, Mr. Zheng revealed that the company's R&D team is closely following market trends and has achieved significant breakthroughs in the development of intermediates related to weight-loss drugs. These products have now entered the stage of large-scale mass production and are expected to provide downstream pharmaceutical companies with more key material support.
Mr. Zheng stated that as long as Lizhuo consistently adheres to technological innovation as its driving force, it is committed to providing global pharmaceutical companies with high-quality, high-value-added pharmaceutical intermediates and APIs.
In the future, the company will continue to increase its R&D investment, deepen cooperation with international and domestic partners, and jointly promote the improvement and development of the innovative drug industry chain.
Post time: Dec-02-2025
